Stock A365270 CURACLE CO.,LTD.
Add to a list
To use this feature you must be a member
Log inSign up

Financials curacle co.,ltd.

Equities

A365270

KR7365270008

Biotechnology & Medical Research

End-of-day quote Korea S.E.
Other stock markets
 03:30:00 10/05/2024 am IST 		5-day change 1st Jan Change
14,990 KRW -3.35% Intraday chart for curacle co.,ltd. -14.29% +28.89%
2023 Curacle Co., Ltd. announced that it has received KRW 20 billion in funding from a group of investors CI
2023 Curacle Co., Ltd. announced that it expects to receive KRW 20 billion in funding from a group of investors CI

Valuation

Fiscal Period: December 2021 2022 2023
Capitalization 1 3,10,021 1,57,152 1,61,138
Enterprise Value (EV) 1 2,72,491 1,33,705 1,38,729
P/E ratio -41.8 x -13.7 x -13.9 x
Yield - - -
Capitalization / Revenue 49.6 x 43.9 x 15.7 x
EV / Revenue 43.6 x 37.3 x 13.5 x
EV / EBITDA -42 x -11.6 x -14.1 x
EV / FCF -14.7 x -12.1 x -22.2 x
FCF Yield -6.82% -8.24% -4.5%
Price to Book 5.64 x 3.4 x 3.83 x
Nbr of stocks (in thousands) 13,687 13,846 13,855
Reference price 2 22,650 11,350 11,630
Announcement Date 01/03/22 01/03/23 29/02/24
1KRW in Million2KRW
Estimates

Income Statement Evolution (Annual data)

Fiscal Period: December 2021 2022 2023
Net sales 1 6,255 3,583 10,294
EBITDA 1 -6,487 -11,480 -9,865
EBIT 1 -6,870 -11,982 -10,508
Operating Margin -109.83% -334.43% -102.08%
Earnings before Tax (EBT) 1 -6,678 -11,406 -11,586
Net income 1 -6,678 -11,406 -11,586
Net margin -106.76% -318.34% -112.54%
EPS 2 -541.5 -828.5 -837.0
Free Cash Flow 1 -18,575 -11,017 -6,244
FCF margin -296.97% -307.48% -60.66%
FCF Conversion (EBITDA) - - -
FCF Conversion (Net income) - - -
Dividend per Share - - -
Announcement Date 01/03/22 01/03/23 29/02/24
1KRW in Million2KRW
Estimates

Balance Sheet Analysis

Fiscal Period: December 2021 2022 2023
Net Debt 1 - - -
Net Cash position 1 37,530 23,446 22,408
Leverage (Debt/EBITDA) - - -
Free Cash Flow 1 -18,575 -11,017 -6,244
ROE (net income / shareholders' equity) -20% -22.5% -26.3%
ROA (Net income/ Total Assets) -11% -12.4% -10.5%
Assets 1 60,827 92,284 1,10,644
Book Value Per Share 2 4,019 3,335 3,036
Cash Flow per Share 2 763.0 615.0 931.0
Capex 1 17,449 3,411 120
Capex / Sales 278.97% 95.21% 1.16%
Announcement Date 01/03/22 01/03/23 29/02/24
1KRW in Million2KRW
Estimates

EPS & Dividend

Year-on-year evolution of the PER

Change in Enterprise Value/EBITDA

Sector Bio Therapeutic Drugs

1st Jan change Capi.
CURACLE CO.,LTD. Stock curacle co.,ltd.
+28.89% 157M
VERTEX PHARMACEUTICALS INCORPORATED Stock Vertex Pharmaceuticals Incorporated
+2.98% 108B
REGENERON PHARMACEUTICALS, INC. Stock Regeneron Pharmaceuticals, Inc.
+11.15% 104B
ARGENX SE Stock argenx SE
+1.69% 22.33B
BIONTECH SE Stock BioNTech SE
-11.88% 22.19B
GENMAB A/S Stock Genmab A/S
-7.05% 18.69B
WUXI APPTEC CO., LTD. Stock WuXi AppTec Co., Ltd.
-38.36% 17.74B
BEIGENE, LTD. Stock BeiGene, Ltd.
-10.19% 17.64B
NEUROCRINE BIOSCIENCES, INC. Stock Neurocrine Biosciences, Inc.
+5.69% 14.05B
SAREPTA THERAPEUTICS, INC. Stock Sarepta Therapeutics, Inc.
+34.78% 12.51B
Bio Therapeutic Drugs
  1. Stock Market
  2. Equities
  3. A365270 Stock
  4. Financials curacle co.,ltd.
-40% Limited Time Offer: Our subscriptions help you unlock hidden opportunities.
SIGN UP NOW